Slide 1: Innovation in gene synthesis & delivery
Innovation in gene synthesis & delivery June 2023 1
Slide 2: Presenters
Presenters Dr. Heikki Lanckriet, PhD. David Roth CEO & CSO CFO 2
Slide 3: Disclaimer
Disclaimer This document is intended for shareholders, prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estim
Slide 4: Agenda
Agenda • Review • Technologies • Applications • Market Opportunity • Milestones • Commercial Development • Business Strategy • Objectives • Financials • Summary Investor Presentation 4
Slide 5: Review
@ —e ® 2:4basebio
Slide 6: Disruptive Platform Technologies and Products
Disruptive Platform Technologies and Products Synthetic and safer alternative to plasmid Flexible platform enabling application specific products 4bbDNA Rapid product in weeks rather than months 4basebi Proprietary patent protected o Listed on AIM Ticker: 4BB, 85 FTE Alternative to AAVs and LNPs Tar
Slide 7: Applications
Applications 4basebio’s four DNA products are optimised Hermes™ delivery platform is able to for specific applications deliver a range of nucleic acid payloads, including DNA, mRNA, miRNA, and protein 7
Slide 8: Market Opportunity
Market Opportunity Syn Biology $12B 21% CAGR Non-viral viral vectors $2.3bn $1B+ 19.3% CAGR 25% CAGR pDNA $1.3B 18% CAGR DNA mRNA vaccines Vax/Tx $400m+ $30bn+ 6% CAGR 2% CAGR Gene editing $5bn 18% CAGR 8
Slide 9: Milestones
Milestones Commercial evaluation programs across AAV, mRNA, gene editing and vaccines DNA Product Completed clean rooms validation in 2022 with QMS qualification during 2023 Clean Able to manufacture Rooms GMP compliant product for AAV and mRNA programs GMP compliance First DNA and Hermes™ revenues
Slide 10: Commercial Development
O —@® —@ oe 2:4basebio Commercial Development 10
Slide 11: Commercial Life Cycle
Commercial Life Cycle EXPLORATION Time EVALUATION ONBOARDING RUO Increasing Product HQ for Sale revenue GMP 11
Slide 12: Customer Product Stages
Customer Product Stages low value 1 RUO off-the-shelf evaluation 2 RUO custom batch discovery & early pre-clinical 3 HQ custom batch late pre-clinical / GLP tox phase 4 GMP custom batch clinical phases high value Early stage revenue and the timing of follow on projects is unpredictable 12
Slide 13: Business Strategy
—€)} Business Strategy ,” ON 2:4basebio 13
Slide 14: Corporate Development
Corporate Development DNA • Increase the Group’s internal resource to onboard customers, manage projects and manufacture product • Scale revenues through RUO and HQ to GMP • Develop the DNA arm • Become a CDMO for the provision into a CDMO; and of DNA for cell & gene therapy and vaccine applications
Slide 15: Shareholder Value Realisation
Shareholder Value Realisation • CDMO • Ongoing revenue growth CDMO • Profitability • Corporate Transaction Licensing • Technology validation • Licensing • Clinical programmes • DNA to other CDMOs Transaction • Non-viral platform 15
Slide 16: Valuation Events
Valuation Events Technology Clinical Validation Programs Revenue GMP Growth Qualification 16
Slide 17: Objectives
—p Objectives ,” ON 2:4basebio 7
Slide 18: Principal Objectives
Principal Objectives 2023 2024 Manufacture Commence GMP GMP batches for accreditation sale Grow Supply into Commercial clinical Pipeline & programs revenue New DNA products Scale opening Revenues additional markets Value accretive events 18
Slide 19: Financials
@ —e —Q@ Financials ® ‘Ldbasebio 19
Slide 20: Financial Results 2022
Financial Results 2022 Consolidated statement of profit or loss and other comprehensive income for the year ended 31 December 2022 [in £‘000] 2022 2021 Revenues 268 338 Cost of goods sold (29) (69) Gross profit 239 269 Sales and marketing expenses (245) (132) Administration expenses (2,711) (1,725)
Slide 21: Financial Results 2022
Financial Results 2022 Consolidated statement of financial position 31 December 2022 [in £’000] 2022 2021 Assets Non-current assets 5,792 4,060 Other current assets 1,546 1,056 Cash and cash equivalents 4,351 9,586 Current assets 5,897 10,642 Total assets 11,689 14,702 Liabilities Financial liabilit
Slide 22: Financial Results 2022
Financial Results 2022 Consolidated statement of cash flows for the year ended 31 December 2022 [in £’000] 2022 2021 Net loss for the period (5,150) (3,235) Adjustments to reconcile net loss for the period to net cashflows Income taxes (779) (405) Interest charge 89 113 Depreciation of property, pla
Slide 23: Financial Position 2023
Financial Position 2023 • Cash burn set to increase in 2023 • Company will draw down on 2Invest loan facility during the course of the year • Cash runway expected at least into 2025 23
Slide 24: Summary
O —®@ On 2:4basebio 24
Slide 25: Summary
Summary Disruptive technologies Addressing Strong and high growth growing IP markets portfolio Shareholder value Secured first Client pipeline clinical supply building deal strongly GMP compliance 25
Slide 26: www.4basebio.com info@4basebio.com
www.4basebio.com info@4basebio.com 26